EVENTS
MEDIA
11
May
2021
4
May
2021
PRESS RELEASES
November 24 | 2021
Prilenia to Present at the 4th Annual Evercore ISI HealthCONx Conference
November 17 | 2021
Prilenia Receives Fast Track Designation for Pridopidine for the Treatment of Huntington’s Disease
October 20 | 2021
Prilenia and Huntington Study Group Announce Completion of Patient Enrollment Ahead of Schedule in Global Phase 3 PROOF-HD Huntington’s Disease Clinical Trial
July 12 | 2021
FDA Grants Orphan Drug Designation for pridopidine for the Treatment of Amyotrophic Lateral Sclerosis (ALS)
July 8 | 2021
Prilenia’s Phase 3 Huntington’s Disease Clinical Trial Achieves
50% Enrollment
June 29 | 2021
Prilenia receives positive EMA opinion on Orphan Drug Designation
for pridopidine in ALS
May 25 | 2021
New research supports pridopidine’s neuroprotective properties in Huntington’s Disease models
May 13 | 2021
Prilenia Achieves 25% Enrollment in its phase 3 HD trial and appoints
Dr. Goldberg as CSO
April 1 | 2021
Prilenia to Present at Stifel, BMO, Needham and the European Biotech Investor Days
January 28 | 2021
Prilenia Enrolls First Subject in Europe in its PROOF-HD Phase 3 Clinical Trial for Huntington’s Disease
January 8 | 2021
Prilenia Announces First Patient Enrolled for Pridopidine Phase 2/3 Platform Trial for ALS
December 16 | 2020
Additional analyses of Efficacy and Safety of Pridopidine for Huntington’s Disease demonstrate positive effect on functional capacity
October 27 | 2020
Prilenia Enrolls First Patients into its PROOF-HD Phase 3 Clinical Trial for Huntington’s Disease in the United State
September 17 | 2020
Huntington Study Group Announces A Partnership with Prilenia Therapeutics to Conduct A Global Phase 3 Clinical Study of Pridopidine in Huntington’s Disease
September 10 | 2021
Henk Schuring joins Prilenia as Chief Regulatory and Commercialization Officer
September 18 | 2019
Prilenia’s Pridopidine chosen to participate in the first ever ALS platform trial by the Sean M. Healey & AMG center for ALS at Mass General